new modern way to approach cancer - 5th international biobran workshop

New Modern Way to Approach Cancer

9 – 11 June 2017

Krakow

Poland

5th International Biobran Workshop

Speaker: Serge Jurasunas N.D., M.D. (Hom)

Professor of Naturopathic Oncology

www.sergejurasunas.com

Up to now the conventional treatments of

surgery, chemotherapy and radiotherapy have

reached a maximum plateau of EFFICACY

and we can EXPECT only little PROGRESS

or NONE in the future.

Professor Dominique Belpomme, Oncologist author

of the book “Guerir du cancer ou s’en Proteger”.

France

2

Serge Jurasunas N.D.M.D. (Hom)

Pioneer in Natural Medicine and Naturopathic Oncology

Practitioner – Researcher – Author – 50 years of practice

Author of 7 books

2017 New book:

Health and Disease Begin in the Colon -

Featuring Professor Serge Jurasunas’

Natural Medicine


Blog:

http:/naturopathiconcology.blogspot.com

3

Presentation

- The problem of modern Oncology

- New Hallmarks of Cancer

- Apoptosis, Immunotherapy, Angiogenesis

- Biobran Mgn3

- Liquid Cartilage Extract (LCE)

- Curcumin

- Case examples

4


Strategic Immunotherapy, Apoptosis and Angiogenesis

Professor Serge Jurasunas Delivering His Lecture, “New Modern Way to Treat Cancer” at the Biobran Conference

5

Where are We Today with Cancer ?

Despite the progress in

Oncology and some benefit in

the gold standard of palliative

therapy, surgery and radiation,

conventional treatment has not

achieved the hope and

expectation to cure cancer.

In metastasic cancer, Oncology

is not better than 30 years ago.

There has been no significant

change in the survival rate.

6

Problems of Conventional Oncology

→ Mul)drug Resistance

→ Radiotherapy resistance

→ Chemotherapy is very toxic and may be

fatal to patients

→ Many An)cancer drugs show no

efficacy

→ Metastasis cancer is incurable and

responsible for 90% of deaths

7



A strong need for new less toxic and more efficient approaches to

cancer treatment.

Three main Hallmarks responsable for tumor growth,

metastasis condition and tumor invasion:

1 – Apoptosis

2 – Angiogenesis

3 – Immune Surveillance

“Hallmarks of Cancer. The Next Generation.”

Hanahan D., Weinberg R.A. (Cell journal 2000)

8

The p53 Tumor Suppresssor Protein

The p53 tumor suppressor protein is activated when DNA is damaged. The

p53 gene is called the “Guardian Angel of the Genome”

p53 protein activates

genes for proteins

that:

- Prevent cells

entering S phase

- Repair DNA

- Cause apoptosis

(if DNA is

irreparableDNA repair

Apoptosis

Cell cannot enter S phase

9



10

p53 Transcriptionally Controls BCL-2 and BAX to

Mediate Apoptosis

11

p53 Mutations in Cancer

■ p53 is the most commonly

mutated gene harbored in

more than half of all

cancers.

■ p53 inactivated or

mutated appears necessary

to develop many forms of

cancer.

■ Restoring p53 WT

function or activation may

offer a therapeutic benefit.

Read: Serge Jurasunas - The p53 Tumor Supressor Gene Understanding p53 Based

Anticancer Therapies Utilizing Dietary Agents. Townsend Letter – August/Sept 2015

Growth of Xenograft Tumors

Tumors with intact

p53 gene regressed

during the treatment,

whereas the tumors

with defective p53

genes continued to

grow.

12

Video from a Researcher at the University of Singapore

(From My Science Work)

A number of recent articles published in various countries have

shown that reactivating the immune system to treat cancer is now

attracting oncology.14

Reactivating the Immune System Against Cancer: A Role for Natural Compounds

16

Biobran/Mgn3

The BREAKTHROUGH in Immuno-Oncology

Two decades of studies show that Biobran/Mgn3 a

natural compound made from modified rice bran is a

potent immunomodulator of NK cells, our most

important line of defense against cancer including T-

cells, B-cells and global immune system function.





Biobran a Biological Response Modifier

Biobran is a hemicellulose complex, a dietary fiber containing

Arabinoxylan as a major component which is produced from modified rice

bran and enzymatically treated with an extract from mycellia shitake

mushroom.

Before the process

Arabinoxylan itself has

no immunostimulating

activity until the long

polyssacharides

molecules are broken up

into smaller components.

17

Digestion, Absorption and Function of Biobran

Dietary fibers are eliminated by the intestine but Biobran is absorbed in the

small intestine practically undigested entering into the blood to become a

nutritional food that activates N.K.cells and optimizes immune function when

taken orally.18

Biobran increases the Curve of NK cells

If you prescribe 2g of

Biobran to volunteers then

you can see a curve of NK

cells increasing about 60%

after two weeks. But if you

continue, you can achieve

up to 200 even 300% or

more NK cell number and

activity.

NK cells are here but not

activated to release their

toxic enzymes (perforin)

through the membrane of

cancer cells.

Ghoneum M. “Enhancement of Human natural killer cells activity by modified

arabinoxylan from rice bran. (Mgn3) Int. Immunotherapy 1998. XIV.89-99

19

-Cancer patients on chemotherapy have a depressed NK cell

activity attributed to a decrease or absence of perforin and

granzymes (1).

-Mgn3 Biobran studies have shown that the treatment causes

an increase in the granular content (perforin and granzymes)

of NK cells.

-It also results in an increased NK cell binding capacity to

cancer cells.

(1) Culler S.P. Brunet M., Martin S.J. – Ganzymes in cancer and immunity – Cell Death Differ.

2010.17-616-623

21



22

NK Immunorestoration of Cancer Patients by Biobran/Mgn3

Figure 3: Cytocentrifuge preparation of two K562

tumor cells undergoing destruction by one NK cell.

NK cells were activated by MGN-3

a) First step in the process represented by the

binding of an NK cell to tumor cells. (Giema,

X740)

b) Preparation showing one tumor cell is dead.

(Giema, X740)

c) Preparation showing both tumor cells are dead

while an NK cell in between is still alive.

(Giema, X740)

d) Cytocentrifuge preparation showing NK cell

has detached itself from the dead tumor cells.

(Giema, X740)



23

NK Cells Killing Cancer Cells



Significant Synergism

24

25

Biobran Enhances the Effect of Chemotherapy Leading to Effective

Treatment at Low Dosage with Less Toxic Effect and More Results



Some of Our Clients Have Been Taking Biobran on Long-Term Follow

Up from 2-4-7 Years Without Toxicity

26

27

Biobran Improves Cancer Patient Survival Rates

205 cancer patients with progressive and metastatic disease stage (III-IV) after conventional

treatment with surgery and adjuvant chemotherapy.

The Biobran group received 2 gr of Biobran per day, the control group did not receive anything.

Biobran Group Control Group

2 year survival 52/96 (54.2% 19/63 (33.9%)

NK activity

20% 17/40 (42.5%) 2/16 (12.5%)

20% - 40% 10/35 (51.4%) 7/25 (28.0%)

40% 17/21 (81.0% 10/15 (66%)

There are a significant differences compared to control group. P<0.01 P>0.05 .

52 of the patients in Biobran group survive 2 years.

If patients have higher than 40% activity of the NK cells prior to go into study, they have a very

high survival rate compared to the control group.

Takahata K. – Abstract 3rd Annual meeting of the Japanese Society for complementary Medicine – Treatment,

2000.

A New Approach to Cancer – Antiangiogenic Therapy

One promising new approach to Cancer Therapy is the use of drugs that inhibit Tumor

Growth by interfering with the Angiogenic mechanism that shuts off tumor blood

vessels. This is a non-toxic and selective therapy for Tumors.28



29

Shark cartilage is an avascular tissue that contains components able to

stop the development of blood vessels needed for tumor growth. Shark is a

particularly suitable source, since its skeleton is enterely formed by

cartilage and its antiangiogenetic activity is 100,000 times that of

mammalian cartilage.

L.C.E is a concentrated hydrosoluble extract of liquid cartilage that contains

biologically active mucopolysaccharides and proteins with strong

antiangiogenic properties (1).

L.C.E. may simultaneously target many different aspects of the angiogenic

cascade to prevent the tumor from making new blood vessels and to

destroy existing ones.

In vitro L.C.E. Interferes with the VEGF binding and signaling to VEGF

receptors, that tumors need to attract and build new blood vessels, thus

inhibit migration of endothelial cells.

The Effects of Liquid Cartilage Extract (L.C.E.)

as an Angiogenic Inhibitor

30

Cancers that Have Successfuly Responded to L.C.E.

Thousands of patients have received L.C.E.

This includes a variety of different cancer types mostly solid tumors but also non

solid tumors.

Prostate

Breast

Lung

Kidney

Lymphoma

Glioma

Results of animal studies of the effect of L.C.E. show a significant decrease in the

number of lung nodules when used alone or in combination with cisplatin. L.C.E

decreases bone metastasis in mice.

These studies confirm with our own cancer cases, which we treat with lung

nodules, especially those with bone metastasis. Non-operable tumors also respond

well to L.C.E. together with chemotherapy regímen. I have had some isolated cases

of breast cancer with no surgery and chemotherapy where the tumor was

eliminated as well as the bone metastasis. Our patients have taken L.C.E. for a

long-term period without toxicity.

31

L.C.E. is available in 30ml concentrate vials (frozen liquid) or less

concentrated in a non frozen vial both taken orally and shown to be

bioavailable (2) and non-toxic in long term administration (3) compared to

antiangiogenic drugs such as Avastin.

(1)Lee A., and Langer R. – Shark Cartilage contains inhibitors of angiogenesis – Science 1983, 221-

1185-1187

(2)Bilodeau D – A liquid extract with antiangiogenic and blood modulating activities, for the

support of first line cancer treatment. 1st International Conference of the Society of Integrative

Oncology. Poster nº36-NY 2004-Nov 17.19

(3)Berbari P., Thibodeau ª, Germain L., Saint-Cyr, M. Gaudieau P., El-Khouti S., Dupont E., Garrel

DR. Oral Bioavailability of a Liquid Cartilage Extract: A Human Clinical Trial – J. Surg Research

1999-87-108-113.

The Effects of the Liquid Cartilage Extract (L.C.E.)

as an Angiogenic Inhibitor

32

Liquid Cartilage Extract

Multiple Activities

Liquid Cartilage Extract

Commercial name: COMITRIS (Douglas Labs – USA)

Available in frozen liquid vials of 14 ml for therapeutic application.

Posology: To be taken orally and shown to be bioavailable (1)

L.C.E. is non toxic in long term administration.

(1) Berberi P., Thibodeau A., Germain L., Saint-Cyr M., Gaudieau P., El-Khouti S., Dupont E., Garrel

D.R. – Oral Bioavailability of a liquid cartilage extract. A human clinical Trial – J.Surgery Research.

1999-87-108-11334

Read my conferences on Cancer and Angiogenesis:.

“Angiogenesis and Cancer – A Novel Approach”

“Liquid Cartilage Extract as a Natural Nutritional

Adjuvant for Conventional Therapies”

4th European Congress of Anti-Aging Medicine

Oct.17-19-2008, Paris, France (online or at:

www.sergejurasunas.com)

8th Congress for Nutri Phytotherapy

March 2007, Brussels, Belgium

35



CURCUMIN – A Potent Anticancer Agent

(Yellow ingredient derived from curcuma longa.l one of the most

extensively investigated phytochemical compounds with ANTICANCER

properties. (1)

(1) Anticancer potential of curcuma. An old spice with new targets. Bharat B. Aggarwal Ph.D. University of

Texas M.D. Anderson Cancer Center. Houston. TX.USA 36



Effects of Curcumin on the Interaction with Multiple

Cell Signaling Proteins, Cancer and Chemotherapy

Apoptosis induction Downregulated BcL2-Survivin, increased p53 gene

expression, Bax and P21 gene expression,

Stimulation of caspases 3-7 activity. Inhibits NFKB

Inhibition of the cell cycle

progression

G2/M arrests (also GO, G1) (pathway of many

anticancer agents)

Inhibition of angiogenesis Inhibition of VEGF, NFKB activity

Inhibition of metastasis and

invasion

Inhibition of MMP’s 3,6,7,8 expression or activity.

Anti-inflammatory Suppression of COX2 expression or activity,

downregulate Nuclear Factor Kappa B (NFKB) itself

responsable for tumor growth, metastasis invasion,

suppress immune function actived VEGF. MMP’s to

favor angiogenesis

37

Human Melanoma Cell Line SK-MEL-37 Cells have been Treated with 15uM

and 20uM of Curcumin for 24 hours: (B and D) Entering into Apoptosis. (A

and C Untreated Cells).

These cells have demonstrated to be resistant to doxorubicin, cisplatin in

culture but sensitive to curcumin treatment.

Marcella Lemos Carneiro – Morphological alterations and Go/G1 cell cycle arrest induced by curcumin in human SK-

MEL-37 melanoma cells. Braz.arch.Biol. Technol.Vol.53 n.2.Curitiba.April.2010

Curcumin potentializes the

effectiveness of

chemotherapy in a variety of

cancers including breast,

ovarian, colon and pancreatic

and could become a

promising tool.

38

39

Curcumin Increases the Sensitivity of Drug Treatment in

Breast, Ovarian, Cervical, Pancreas and Colon Cancer

- 5 Fu

- Taxol

- Pactitaxel

- Cisplatin

- Adramycin

- Daunorubicin

Koo J.Y. et al, 2002, VBS et al. 2003, Chan M.M., 2003, Chuang S.E. et al, 2002



A Study in Breast Cancer

(Bayet-Robert and Collegues 2010)

Oral curcumin and docetaxel administered to

INOPERABLE breast cancer patients with advanced

tumors and metastasis, became OPERABLE after the

combination therapy.

Patients had LOWERED tumor MARKERS and V.E.G.F.

levels indicating REDUCED cancer cell SURVIVAL and

ANGIOGENESIS, tumor SIZE and inflammation. (1)

(1) Serge Jurasunas – Complementary Approach to Breast Cancer. A Case with Multiple Liver

Metastasis is Free from Disease. Townsend Letter August/September 2015.40



Synergetic Effect of Biobran MGn3 and Curcumin

in Cancer Treatment with Chemotherapy

- Faster reduction and/or elimination of secondary

nodules in cancer recurrence.

-Significant reduction of large tumors when

taken together with chemotherapy.

- Advanced cancers with multiple metastasis

(Liver, lung, etc.), having received poor

prognosis with a combination of chemotherapy,

has resulted in prolongation of lifespan (6-8

years) with maintenance, along with an improved

quality of life (QOL). 41



Curcumin Preparation (Lecifarma Lab – Portugal)

Brand name: Curcumino

Complex

Presentation: Sachets of

100mg of liquid curcumin

Developed for high absortion

and bioavaibility

Tests conducted at the

Faculty of Pharmacy –

University of Lisbon –

Portugal show: 66%

absorption on the left (gray)

column, 112% on the right

(orange)43

0

5

10

15

20

25

30

35

Compartimento basolateral

(através da barreira intestinal)

Compartimento intracelular

(dentro das celulas

intestinais)

Pe

rme

açã

o d

a C

urc

um

ina

(%

)

Curcumina pó

CURCUMINO

COMPLEX

+115%

+66%

45

Protocol for Cancer PatientsBiobran

1 sachet of 1mg 3 times per day, 20 minutes after a meal.

L.C.E. (Comitris)

1 ampoule of 14ml sublingual to be kept 5 minutes in the mouth

before swallowing.

Curcumin

1 sachet of 1500 mg liquid diluted in water to take 3 times per

day between meals.

Additionaly as support to nutritional need, detoxification,

boosting mitochondria function and activating ATP energy.

Enzyme Yeast Cells (Zell-oxygen).

Anticancer diet, cocktails of fresh vegetable juices.



A Few Interesting Case Histories

We Don’t Cure All the Cancers but…

-Many cases after 25-30 years are alive and doing well.

-Several have had a 10 year extension.

-Several advanced cases have improved their quality of life with a life

spent up to 7 years , including prostate cancer, multiple myeloma,

breast cancer, and pancreatic cancer.

-Unfortunately many cases come in too late that end up fatal from

excess chemotherapy.

-Overall our treatments have demonstrated efficacy, help the patient

by reducing toxic effects, improve chemotherapy effectiveness,

quality of life and increase life expectancy.

46

47

10/11/2005 – Bad physical condition – metastasis to bone skeleton – PSA 354 nl/ml

Treatment – L.C.E. (Comitris) – Immunomodulator (Biobran) 3g per day

12/01/2006 - PSA 53.6 nl/ml - After 3 months PSA 1.4 nl/ml

After 5 months elimination of almost all the bone metastasis.

Patient Male – 73 years old – Prostate Cancer

Clinical story: Adenocarcinoma of the Prostate – Gleason 7 (3+4) -

Advanced case – No Surgery or Chemotherapy/Radiation.

p53 Gene Expression

p53 Protein Level mutated

p53 Protein Level normal

Not detectable

10.88 units/µl of plasma

Not detectable

340 units/µl of plasma

Reference range:

10-50 units/µl of plasma

Reference range:

0,33 units/µl of plasma

Reference range:

10 units

Reference range:

10-100 units

Survivin Gene Expression

BCL2 Gene Expression

BAX Gene Expression

Not detectable

Patient M – 81 years old – Recurrence of Colon Cancer

- Liver Metastasis

1st Test: 9/3/2011 2nd Test: 11/8/2011

p53 Gene Expression

1.180 units/ml of plasma

p53 Protein Level nnormal

Not detectable

p53 Protein Level

mutated

Not detectable

BCL2 Gene Expression

Not detectable

Not detectable

BAX Gene Expression

409 units/ml of plasma

Apoptosis

Survivin Gene Expression


P21 Gene Expression

Not detectable

P21 Gene Expression

Not detectable

Reference range:

10 units

Reference range:

10-50 units

2 pools of

resistance

48

F.41 years – Asympthomatic Prime Lesions 18 cm –

Secondary Lesions 8 cm

Combination of chemotherapy with our complementary treatment that

targets apoptosis, angiogenesis, immune activity – Anticancer Diet 49

Advanced Gastric Cancer - Results of Blood Analysis

July 2015 April 2015 July 2015 April 2015

Lesion of

30,1 mmLesion of

48,7 mm

Lesion of

18 cm

p53 Gene Expression

p53 Protein Level

mutated

p53 Protein Level normal



1 unit/µl of plasma


Reference range:

10-50 units/µl of plasma

Reference range:

0,10 – 1,00 units/µl of plasma

Reference range:

5 - 15 units

Tumor Marker 2 – Pyruvate Kinase

TM2.PK

Advanced Gastric Cancer - Result of Blood Analysis

1st Test: 28/04/2015 2nd Test: 26/06/2015

p53 Gene Expression


p53 Protein Level nnormal


p53 Protein Level mutated

Not detectable


Tumor Marker 2 – Pyruvate Kinase

TM2.PK

We significantly increased the expression of the p53 gene about 4 times and increased normal p53 protein only to a certain extent . We reversed the production of mutant protein to normal wild type. TM2.PK activity decreased to an almost normal range.

After the applied therapy

50

51

Advanced Gastric Cancer - Photo taken on May, 2017

52

Breast Cancer with Multiple Metastasis to Liver

Complete case published in Townsend Letter August/Sept 2014 or


Patient female, 44 years old diagnosed in October 2011 with a stage III left breast

cancer, with dissemination of about 30 lesions to the liver; up to 1,5cm size for many

localized in the left lobe, and segment III and IV of the right lobe.

Breast tumor was about 3.5cm with inflammation spread to neighboring tissues; many

swollen lymph nodes were diagnosed on the left part of the neck. Chemotherapy was

suggested before surgery to reduce the tumor and the inflammation.

January 2012 – The patient came into our clinic suffering from adverse side effects

having had very little response from chemotherapy. She felt tired, nausea, loss of

appetite, anxiety. We had taken 3 different tests: Live Blood Analysis, Oxidative Dried

Blood Test and Molecular Markers Testing. These tests showed very high BCL2

activity, low BAX gene activity and especially very high VEGF levels showing activated

angiogenesis in the solid tumor.

Treatment – L.C.E., Biobran MGN-3, Curcumin and Anticancer Diet

After 2 months of treatment the inflammation was almost gone, in the same way as

the swallowed ganglions and reduced tumor. Surgery was done followed by

chemotherapy and our treatment. In 2003 a new scan showed total elimination of the

30 liver nodules and complete remission. In 2017 the patient is still in remission but

still comes in regularly for our check up exams.

53

THE ANTI-TUMOUR EFFECTS OF THE APPLIED TREATMENT

02/12/12370 05/12/12461Ref. Range

p53 gene expression200 427 10-50 units/ul of plasma

p53 level mutatedND ND ND units/ml of plasma

p53 level wildND 0,4 0.10-1.00 units/ml of

plasma

Bcl-2 gene expression8000 796 <10 units/ul of plasma

Bax gene expression167 1543 10-100 units/ul of plasma

Bcl-2/Baxratio 0.02 1.93

Surviving gene expression171 900 <10 units/ul of plasma

P21 gene expression139 738 10-50 units/ul of plasma

Surviving/p21ratio 0.8 0.8

VegF gene expression2353 ND 10-100 units/ul of plasma

A Complementary Approach to Breast Cancer: A Case with Multiple Liver

Metastasis is Free from Disease Complete Report – Townsend Letter Magazine – August/Sept 2014

Breast Cancer with Multiple Metastasis to the Liver

54

Breast Carcinoma Stage IV with Multiple Metastasis to Ganglions,

Liver, Bone, Pleura and One Nodule to Right Lung

Patient female – 42 years old – Breast carcinoma stage IV with multiple metastasis

to ganglions, liver, bone, pleura and one nodule to right lung.

The patient underwent a radical mastectomy and started chemotherapy on October

2015. A February, 2016 scan showed more dissemination of metastasis, which

increased in April, with poor physical condition. There was strong resistance from

cancer cells to chemotherapy with more dissemination of metastasis.

The patient came to us in May 2016 and immediatly started our treatment.

Biobran MGN-3, 3 gr per day – Curcumin, 4,5 gr per day – Enzyme yeast cells

preparation, 40 ml per day – Coenzyme Q10, 300 mg per day followed by an

aggressive anticancer diet and plenty of vegetable juices which is important in any

cancer treatment.

August 2016, a new scan showed major improvement, about a 70% reduction in nodule

size, demonstrating synergy with our combination therapy with chemotherapy by

increasing effectiveness by targeting apoptosis, angiogenesis and immune cell activity.

Results in the next slide reveal the patient got worse from chemotherapy alone, but after 3

months had a much better scan after our complementary therapy.

55

Breast Carcinoma Stage IV with Multiple Metastasis to Ganglions,

Liver, B one, Pleura and One Nodule to the Right Lung

56

Advanced Prostate Cancer (1)

Patient male – 71 years old – Advanced prostate cancer.

The patient was diagnosed in 2005 with a prostate cancer with

dessimination of bone metastasis. Very high PSA 1.260 ng/ml. No surgery,

chemotherapy or radiation was suggested but only a hormonal therapy,

but without result. The patient was in a very bad condition.

2006 – The patient started our alternative treatment.

L.C.E. Biobran Mgn-3, prostasol (herbal composition) Imupros (vitamins,

trace elements, lycopene, ginseng, etc…) together with an anticancer diet.

After 4 months the patient felt better and gradually started to improve. PSA

decreased to 328 ng/ml. After 8 months to 58 ng/ml and to 2.8 ng/ml and

final to 1.58 ng/ml.

After 6 months of treatment new bone scan showed a 50% decrease of

bone lesions and after one year a total elimination. The treatment was

followed during the whole year.

58

Cancer of the Colon with Metastasis to Lung and Liver

Patient female – 56 years old – Diagnosed in May 2010 with colon cancer, stage IV

with metastasis spread to liver.

Surgery and Chemotherapy.

June 2012 - New scan had shown more metastasis to the liver. Patient was

submitted to more chemotherapy with a period of remission.

September 2013 - Recurrence and dessimination of metástases to lung, ganglions

and liver. High tumor marker level Ca 19.9 848 U/ml. CEA 260 ng/ml. The patient

came in our clinic in a desesperate condition.

Treatment: Biobran, Mgn-3, Curcumin, L.C.E., SOD, Alpha lipoic acid, followed by an

aggressive anticancer diet, cocktails of vegetable juices.

2015 - Patient was in bad physical condition, anemic, much coughing from lung

metastasis, felt tired, had chest pains and some difficulty breathing.

59

Results of Molecular Markers Testing:

Normal p53 gene but not activated – absence of normal p53 proteins level – Mutated

protein N.D.

BCL2 overexpression – 459 unit/ul of plasma (normal up to 10 units)

Bax gene expression - 178 units/ul of plasma (reference range 10 units)

BCL2/Bax ratio – 0.4 (bad ratio)

TM2-Pyruvate Kinase level – 231 units/ml of plasma (reference range 5-15)

High metabolic activity of tumor – inflammatory process

2016 - New scan had shown large lung lesions but less active, some smaller, other

calcified. Some good improvement in June 2016, patient felt better.

Scan had shown diminution of the lesions – Ca 19-9 decrease to 150 U/ml and CEA

to 40 ng/ml. Also blood value was normal despite chemotherapy.

2017 - Patient looks in better physical and psychological condition, looks much

better and breathes normally and can do her work. This is a good life extension. In

2015 her doctor told her that she surpassed the 2 year life expectancy statistic. Now

it has been 4 years.

She is still taking her treatment and never stops Biobran and Curcumin intake,

taking LCE with some intervals while keeping on her diet taking vegetable juices.

Cancer of the Colon with Metastasis to Lung and Liver

60

Cancer of the Colon with Metastasis to the Lungs and Liver

The patient in March 2017

Patient female – 50 years old with a metastasic recurrence from

breast cancer (2000) in 2004 with multiple lesions disseminated in the

skeleton. Strong pains and after one year of the new protocol of

chemotherapy a new bone scan (May 2005) showed more

disseminated lesions in comparison to 2004. Poor response and

evolution of the disease. The complete case fully illustrated is

available in English and French.

X Ray of the Spine

After 3 months of

combined therapy +

chemotherapy.

Total elimination of the

very large lesions in the

illium and spine.

Jurasunas Serge, ND

62

Tumor Marker – CA 15.3

113U/ml

55.2 U/ml

23.6 U/ml

June

2005

August

2005

January

2006

63

Patient female – 62 years old

Clinical story: Carcinoma left breast 1988

Partial resection– chemotherapy

2005 – Recurrence: Lung metastasis – However the patient

refused more chemotherapy with the alternative option of CAM.

22/11/2005 - CA 15.3 – 617-U/ml - ACE – 1.25 ng/ml

15/09/2005 – CA.15.3 – 446 U/ml - ACE – 1.23 ng/ml

25/09/2006 – CA 15.3 – 50.2 U/ml - RBC - 5.16 – Hemo 14.9 – WBC’s 4700

06/02/2007 – CA 15.3 – 32 U/ml - RBC - 5.16 – Hemo 14.9

Old CaseBreast Cancer Survivor

1994 – Age 36 years.

Bad prognostic of 18 ganglions

with metastasis – Liver and

bone metastasis.

June 2008 – Age 50 years

Participating as a witness in

our psychological support

group meetings for our cancer

patients – 2017 – The patient is

still in remission at 59 years

old.

Other Clinical Cases (Oldest and Recent)

• Cancer of the pancreas: Remission – 5,7 years lifespan

• Lung cancer: Remission

• Multiple sclerosis: 7 years

• Breast cancer + metastasis liver: Remission 6, 7 years up to now

• Breast cancer with liver metastasis: 26 years

• Brain tumor: 5 years

• Prostate cancer with bone metastasis: 10-15 years

• Bladder Urethra cancer: Remission since 5 years.

• Colon cancer with liver metastasis: 7 years.

Dr. Serge Jurasunas’ Blog: NaturopathicOncology.blogspot.com

https://naturopathiconcology.blogspot.com/2017/05/you-dont-have- to-die-from-cancer.html

65

Oncologist Joseph Brenner M.D., Hegyi Gabriella M.D., Professor Serge Jurasunas N.D., Professor Hijto Tibor, Immuno-Oncologist Dr. Rupert Handgretinger, Professor of Oncology. (L to R)

66

Thank You for

Your Attention!

Don’t Let the Cancer Kill You, but Rather Kill the Cancer.

67

new modern way to approach cancer - 5th international biobran workshop

Health & Medicine